Annals of Hematology

, Volume 83, Issue 11, pp 696–703 | Cite as

Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia

  • Marino Clavio
  • Claudia Venturino
  • Ivana Pierri
  • Alberto Garrone
  • Maurizio Miglino
  • Letizia Canepa
  • Enrico Balleari
  • Manuela Balocco
  • Gian Luca Michelis
  • Filippo Ballerini
  • Marco Gobbi
Original Article


Sixty-two patients with high-risk acute leukemia were treated with the FLAD regimen [3 days of treatment with fludarabine 30 mg/m2, cytarabine (AraC) 2 g/m2, and liposomal daunorubicin 80 mg/m2]. The acute myeloid leukemia (AML) patients were either refractory to standard induction regimens (8), were in first or second relapse (13), or received therapy as first-line treatment [21 patients, 16 were above 60 years of age and 5 had post-myelodysplastic syndrome (MDS) AML]. The acute lymphoblastic leukemia (ALL) patients were treated for relapsed (7) or refractory disease (10). Three patients had chronic myeloid leukemia (CML) in the blastic phase. FLAD was well tolerated by most patients. Ten major infectious complications were recorded while no signs of cardiac toxicity were observed. Five patients (8%) died before day 28 with hypocellular marrow, mainly of infection or hemorrhage, and response could not be evaluated. Complete response rate was 62% and 69% among AML patients treated at diagnosis or for relapsed disease, respectively, and 59% among the ALL patients. Furthermore, FLAD managed to overcome the negative impact of poor prognosis karyotype in ALL patients, since five of the seven patients with t(9;22) or complex karyotype achieved complete remission (CR). Nine patients underwent bone marrow transplantation (BMT). Among the AML patients who were treated at diagnosis or for relapse, the median duration of CR was 7 months (range: 2–18) and 8 months (range: 2–26), respectively. Median survival among these patients was 8 (range: 1–40) and 12 (range: 1–30) months, respectively. Similar values were found in ALL patients. In conclusion, FLAD may be an effective alternative treatment for patients with relapsed AML and for patients with ALL who failed first-line therapy.


AML ALL Liposomal daunorubicin DNX Fludarabine AraC 


  1. 1.
    Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56 [Suppl 1]:8–14Google Scholar
  2. 2.
    Baccarani M, Russo D, Fanin R, Michieli M (2000) Liposomal daunorubicin (Daunoxome) in the treatment of acute lymphocytic leukemia (ALL) (abstract 3110). Blood 96 [Suppl 1]:720aGoogle Scholar
  3. 3.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M (1996) High efficacy of fludarabine-containing therapy (Flag-Flang) in poor risk acute myeloid leukemia. Haematologica 81:513–520PubMedGoogle Scholar
  4. 4.
    Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M (2001) First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukemia. Leuk Lymphoma 40:305–313PubMedGoogle Scholar
  5. 5.
    Cortes J, Estey E, O’Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H (2001) High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92:7–14CrossRefPubMedGoogle Scholar
  6. 6.
    De Witte T, Suciu S, Peetrmans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, Solbu G, Zwierzina H, Muus P (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9:1805–1811PubMedGoogle Scholar
  7. 7.
    Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver, Degos L (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332:1678–1684CrossRefPubMedGoogle Scholar
  8. 8.
    Ermacora A, Michieli M, Pea F, Visani G, Bucalossi A, Russo D (2000) Liposome encapsulated daunorubicin (Daunoxome) for acute leukemia. Haematologica 85:324–325PubMedGoogle Scholar
  9. 9.
    Estey E, Plunkett W, Gandhi V, Beth Rios M, Kantarjian H, Keating MJ (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukaemia. Leuk Lymphoma 9:343–350PubMedGoogle Scholar
  10. 10.
    Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O’Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich EJ, Deisseroth A, Keating M (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671–678PubMedGoogle Scholar
  11. 11.
    Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia) on outcome of AML-type chemotherapy. Blood 90:2969–2977PubMedGoogle Scholar
  12. 12.
    Estey E, Thall P, Pierce S, Cortes J, Beran M, Kantarjian H, Keating M, Andreeff M, Freireich E (1999) Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93:2478–2484PubMedGoogle Scholar
  13. 13.
    Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, Mirto S (1999) Fludarabine, cytarabine, and G-CSF (Flag) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 78:380–384Google Scholar
  14. 14.
    Gajewski JL, Winston GH, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin RE (1989) Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 7:1637–1645PubMedGoogle Scholar
  15. 15.
    Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116–124PubMedGoogle Scholar
  16. 16.
    Gardin C, Chaibi P, De Revel T, Rousselot P, Turlure P, Miclea JM, Nedellec G, Dombret H (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy related acute myelogenous leukemia. Leukemia 11:16–21CrossRefPubMedGoogle Scholar
  17. 17.
    Gobbi M, Pierri I, Clavio M, Quintino S, Masoudi B, Gatto S, Cerri R, Pietrasanta D, Ballerini F, Cavaliere M, Miglino M, Beltrami G, Canepa L, Damasio E (1998) Cost of de novo acute myeloid leukemia induction therapy in adults: comparison between EORTC-GIMEMA AML10 and FLANG regimens. Blood 92 [Suppl 1]:2106Google Scholar
  18. 18.
    Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith C, Hynes H, Balcerzac SP, Appelbaum FR (1998) A double blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood 91:3607–3615PubMedGoogle Scholar
  19. 19.
    Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 7:2322–2333Google Scholar
  20. 20.
    Guaglianone P, Chan K, DelaFlor-Weiss E, Hanisch R, Jeffers S, Sharma D, Muggia F (1994) Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 12:103–110PubMedGoogle Scholar
  21. 21.
    Hoyle CF, De Bastos M, Wheatley K, Sherrington PD, Fisher PJ, Rees JKH, Gray R, Hayhoe FGJ (1989) AML associated with previous cytotoxic therapy or myeloproliferative disorders: results from the MRC’s 9th AML trial. Br J Haematol 72:45–53PubMedGoogle Scholar
  22. 22.
    Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP (2001) A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 112:127–137CrossRefPubMedGoogle Scholar
  23. 23.
    Kantarjian HM, Estey EH, Keating MJ (1993) Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 7:81–107PubMedGoogle Scholar
  24. 24.
    Kern W, Schleyer E, Braess J, Wittmer E, Ohnesorge J, Unterhalt M, Wormann B, Buchner T, Hiddemann W (2001) Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Ann Hematol 80:334–339CrossRefPubMedGoogle Scholar
  25. 25.
    Krishnan B, Hughes D, Ethall M, Potter M, Mehta A, Grant Prentice H (2002) Salvage chemotherapy with fludarabine, cytosine arabinoside, daunoxome and G CSF (FLAG X) in heavily pretreated children and adults with relapsed refractory lymphoproliferative malignances. A single center experience. Blood 100 [Suppl 1]:560aCrossRefGoogle Scholar
  26. 26.
    Leith CP, Kopechy KJ, Godwin J, McConnel T, Slovak ML, Ming CI, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323–3329PubMedGoogle Scholar
  27. 27.
    Liu Yin JA, Johnson PR, Davies JM, Flanagan NG, Gorst DW, Lewis MJ (1991) Mitoxantrone and cytosine arabinoside as first line therapy in elderly patients with acute myeloid leukemia. Br J Haematol 79:415–420PubMedGoogle Scholar
  28. 28.
    Michieli M, Damiani D, Ermacora A, Masolini P, Michielutti A, Michelutti T, Russo D, Pea F, Baccarani M (1999) Liposomal-encapsulated daunorubicin for Pgp-related multidrug resistance. Br J Haematol 106:92–99CrossRefPubMedGoogle Scholar
  29. 29.
    Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F (1998) Fludarabine,cytarabine, and G-CSF (Flag) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58:105–109CrossRefPubMedGoogle Scholar
  30. 30.
    Offidani M, Corvatta L, Centurioni R, Leoni F, Malerba L, Mele A, Marconi M, Scortechini A, Masia MC, Leoni P (2003) High dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. Hematol J 4:47–53CrossRefPubMedGoogle Scholar
  31. 31.
    Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Van De Holt B, Delforge M, Lowenberg B, Verhoef GE (2004) The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood 103:2908–2913CrossRefPubMedGoogle Scholar
  32. 32.
    Pierri I, Miglino M, Gatto S, Venturino C, Quintino S, Beltrami G, Lanino E, Clavio M, Canepa L, Gobbi M (2000) Combination of liposomal daunorubicin (Daunoxome), fludarabine and cytarabine as salvage therapy in relapsed and refractory acute leukemia. Blood 96 [Suppl 2]:215bGoogle Scholar
  33. 33.
    Plunkett W, Gandhi V, Huang P, Roberetson LE, Yang LY, Gregoire V, Estey E, Keating MJ (1993) Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2–12Google Scholar
  34. 34.
    Rowe JM, Andersen JW, Mazza JJ, Bennet JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage CSF in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Blood 86:457–462PubMedGoogle Scholar
  35. 35.
    Russo D, Piccaluga PP, Michieli M, Michelutti T, Visani G, Gugliotta L, Bonini A, Pierri I, Gobbi M, Tiribelli M, Fanin R, Piccolrovazzi S, Baccarani M (2002) Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Hematol 81:462–466CrossRefGoogle Scholar
  36. 36.
    Taylor PR, Reid MM, Stark AN, Bown N, Hamilton PJ, Proctor J (1995) De novo acute myeloid leukemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Leukemia 9:231–237PubMedGoogle Scholar
  37. 37.
    Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, April F, Perona G (1998) Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 12:144–149CrossRefPubMedGoogle Scholar
  38. 38.
    Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Cenacchi A, Carrara P, Clavio M, Gobbi M, Tura S (1996) FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Eur J Haematol 56:308–312PubMedGoogle Scholar
  39. 39.
    Wiles ME, Bell C (1997) Anthracycline efficacy in vitro: cytotoxicity of liposomal/nonliposomal daunorubicin and doxorubicin for multiple tumor cell types. Drug Deliv 4:225–262Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Marino Clavio
    • 1
  • Claudia Venturino
    • 1
  • Ivana Pierri
    • 1
  • Alberto Garrone
    • 1
  • Maurizio Miglino
    • 1
  • Letizia Canepa
    • 1
  • Enrico Balleari
    • 1
  • Manuela Balocco
    • 1
  • Gian Luca Michelis
    • 1
  • Filippo Ballerini
    • 1
  • Marco Gobbi
    • 1
  1. 1.Departments of Haematology and OncologyUniversity of GenovaGenovaItaly

Personalised recommendations